Companies › Merz North America
1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Incobotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 3 | Neuromuscular Agents | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07122193 | Incobotulinumtoxina | Phase 3 | Neuromuscular Agents | Other | Sep 2027 |
AbbVie Biojiva Merz Therapeutics Ipsen Huons Biopharma Merz Aesthetics Merz Pharmaceuticals
Merz Aesthetics Huons Biopharma Merz Therapeutics CUTISS Gameto
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.